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Abstract: Management of systemic lupus erythematosus (SLE) represents a fascinating, 
emerging field. Research has recently provided us with a better understanding of the immuno-
logic alterations of SLE, leading to the creation of immunomodulatory agents designed to disrupt 
specific cell targets and pro-inflammatory pathways. Despite the improvement in the prognosis of 
SLE in the last 50 years with the use of immunosuppressive therapy such as cyclophosphamide 
and mycophenolate mofetil, cytotoxicity remains a major complication of these medications and 
the need for more specific targeted immunotherapy is increasing. Early recognition and treatment 
of SLE with targeted immunotherapy has the potential to improve quality of life and reduce the 
risk of disease flare-ups and complications. In this review, we will explore the role of B-cells 
in the pathogenesis of SLE highlighting current insights into SLE development and manage-
ment. In addition, we will discuss epratuzumab’s role in the treatment of SLE. Epratuzumab is 
a humanized anti-CD22 monoclonal antibody that targets CD22 on B-cell and its role in B-cell 
modulation, migration, function, and inhibition of B-cell receptor signaling. Epratuzumab is cur-
rently in a Phase III study evaluating its efficacy in the management of moderate to severe SLE. 
All published trials on epratuzumab have shown great promise with safe profiles. 
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Introduction 
Systemic lupus erythematosus (SLE) is a chronic complex autoimmune disease with 
variable clinical presentations and disease courses that can be mild, moderate, or life-
threatening depending on the severity of the organs involved.1,2 Patients with SLE have 
hyper-activated B-cells resulting in the production of autoantibodies that contribute to 
different clinical phenotypes.3–5 These autoantibodies contribute to organ involvement 
by various mechanisms such as: immune complex-mediated type III hypersensitivity 
reactions, type II antibody-dependent cytotoxicity, and production of interferon-α, 
tumor necrosis factor, and interleukin-1.6,7 New insights into SLE pathogenesis 
have enhanced the development of biological therapies that specifically target key 
molecules and cells.7,8 Recent therapies have focused on targeting different B-cell 
compartments.9 These include agents that deplete B-cells like anti-CD20 antibodies 
(rituximab and ocrelizumab), agents that modulate B-cell activity (anti-CD22, CD40 
ligand inhibitors), and agents that affect the development of B-cells via B-lymphocyte 
stimulator/B-cell-activating factor of the tumor necrosis factor family (BAFF) or 
proliferation inducing ligand (APRIL) pathways.10–13 In terms of B-cell compartment 
targeted therapy, clinical experience and reports based on a small series of patients who 
received anti-CD20 (rituximab) have demonstrated impressive results but unfortunately 
have failed to achieve the primary outcome in large controlled trials. Several factors 
could have resulted in the failure of rituximab trials including: the trials’ design, in 
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which enrolled patients received highly efficacious standard 
of care (SOC) treatment that made the interpretation of the 
results difficult; underpowered trials with a small sample size; 
as well as stringent endpoints that are hard to achieve.10,11 
Epratuzumab (Anti-CD22 monoclonal antibody) was investi-
gated in moderate to severe SLE with promising results. The 
results of a Phase III trial, Epratuzumab Versus Placebo in 
Subjects with Moderate to Severe General Systemic Lupus 
Erythematosus (EMBODY 1), are still pending. In this 
review, we will explore the role of B-cell and CD22 in the 
pathogenesis of SLE and we will summarize the published 
epratuzumab clinical trials.
Pathogenic role of B-cells and  
CD22 in SLE
The role of B-cells in the pathogenesis of lupus is very 
important and involves antibody-dependent and -independent 
mechanisms. The autoantibody-independent mechanism is 
characterized by antigen presentation, T-cell activation and 
polarization, and dendritic cell modulation.6,14 B-cells interact 
with antigens through B-cell antigen receptors (BCRs).9 BCR 
of auto reactive B-cells can be activated by unclear nuclear 
material, leading to B-cell activation and expression of the 
B-cell survival molecule receptor, BAFF and APRIL.15
There are co-receptors expressed on B-cell surfaces that 
modulate BCR signaling either positively or negatively.16 
CD22, CD72, and Ig (FcRγIIB) are called inhibitory BCR 
co-receptors which prevent over stimulation of B-cells.7 The 
inhibitory BCR co-receptors prevent BCR activation signal-
ing cascades through the recruitment of inhibitory intracel-
lular signaling proteins.17–19 Lyn is a novel member of the 
Src family tyrosine kinase which plays a key role in B-cell 
activation (and is able to activate some negative regulators 
of signaling such as CD22).11,18 On the basis of proposed 
mechanisms outlined above, targeting B-cell membrane 
antigen receptors such as CD20, CD22, and other receptors 
was of interest.
CD22 is a 135 kDa sialo-glycoprotein receptor and a 
B-lymphocyte-restricted member of the immunoglobulin 
superfamily. CD22 is involved in BCR inactivation, con-
trol of B-cell activation and interaction with T-cells, and 
produces a costimulatory signal in primary B-cells.20,21 
CD22 is expressed in pro-B-cells, pre-B-cells, and mature 
B-cells while absent in plasma cells.15 CD22 is essential 
for the development and survival of B-cells.22,23 Elevated 
expression of CD22 and other BCR associated proteins 
on B-lymphocytes has been associated with SLE, chronic 
autoimmune disease, and certain cancers. Current therapies 
for SLE seek to minimize CD22 and other BCR-protein 
expression by destroying B-cells.
Targeting B-cells with epratuzumab
Epratuzumab is an anti-CD22  (recombinant) “humanized” 
IgG1 monoclonal antibody (hLL2), and is 95% of human 
origin with reduced immunogenicity.24,25 Epratuzumab has 
a mean serum half-life of 23.9 days, which is comparable 
to the half-life of human IgG1 and the highest serum levels 
increased with subsequent doses. Epratuzumab is able to 
reduce CD22 with a minimized B-cell destruction effect and 
a minimized impact on the immune system.26 This justifies 
the partial depletion of B-cell numbers with epratuzumab 
as compared to total reduction with rituximab.26 Indeed, 
epratuzumab eliminates up to 45% of circulating B-cells 
while rituximab eliminates 90% of B-cells.27,28 
Rossi et al showed that the mechanism of action of 
epratuzumab on B-cells is twofold; one via binding to 
CD22, which also occurs with F(ab)2, and the other via 
engagement of FcγR-bearing effector cells.28 Epratuzumab 
also induces a marked decrease of CD22 (80%), CD19 
(50%), CD21 (50%), and CD79b (30%), on B-cells’ 
surface in peripheral blood mononuclear cells obtained 
from normal control or SLE patients.28 The other mecha-
nism of action of epratuzumab is trogocytosis which is 
Fc dependent and causes the transfer of epratuzumab-
opsonized B-cells to FcγR-expressing monocytes, natural 
killer cells, and granulocytes. Epratuzumab also induces 
moderate antibody-depen  dent cellular cytotoxicity, without 
complement-dependent cytotoxicity and this can explain 
the absence of infusion related reactions in humans.23,24,29,30 
The pronounced and persistent loss of CD22 on B-cells by 
epratuzumab-mediated internalization and trogocytosis is 
expected to render B-cells less active and less viable, and 
the accompanied decrease of CD19 could further enhance 
this effect.28 
Unlike rituximab which acts only as cytotoxic, epratu-
zumab acts as an immunomodulatory and cytotoxic agent.31 
In the EMBLEM and other trials related to epratuzumab, no 
decreases in immunoglobulin levels were observed, thus it 
speculated that epratuzumab will have a lower risk of infec-
tion compared to rituximab.
 Beum et al found a substantial loss of CD20 on B-cells 
of chronic lymphocytic leukemia patients when rituximab 
plasma concentrations were high, which is related to a phe-
nomenon called antigenic modulation.32 In this phenomenon, 
the removal of rituximab-CD20 complexes is mediated by 
trogocytosis to monocytes, enabling the malignant cells to Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
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escape the effects of the antibody.32 Williams et al showed 
that reducing the dose of rituximab decreases CD20 loss, by 
limiting trogocytosis, and this resulted in an improvement 
of the therapeutic effects of rituximab.33 Rossi et al reported 
that a similar process of antigen modulation via trogocytosis 
induced by anti-CD22 or anti-CD20 antibodies can be 
encountered and affect their therapeutic efficacy.28 This 
could also explain the findings in SLE clinical trials where 
higher doses of epratuzumab did not show an improvement 
compared to the lower doses.28,34
Evidence of clinical efficacy of 
epratuzumab in SLE
 Epratuzumab was initially developed to treat non-Hodgkin’s 
lymphoma and leukemia. It was also tried for the treatment 
of Sjögren’s disease and SLE.35–38 Nearly all of the published 
studies on epratuzumab as an additive to the SOC treatment in 
moderate to severe SLE patients showed improvement in the 
disease activity after the first cycle of therapy. The benefits 
were persistent in those who were maintained on regular 
epratuzumab every 12 weeks as in SL0006 trial.24 
The first trial in SLE was by Dorner et al in 2006.23 It 
was a Phase II open labeled single center study. All patients 
received 360 mg/m2 epratuzumab intravenously every 
2 weeks for a total of four doses. A total of 14 patients with 
moderate disease activity were enrolled in this study. Disease 
activity and the total British Isles Lupus Assessment Group 
(BILAG) index 2004 scores were determined at 6, 10, 18, and 
32 weeks. In all patients, a clinically important improvement 
was achieved with a decrease in BILAG scores by 50% at 
some point during the study. At 6 months, 77% of the patients 
had a 50% decrease in BILAG scores. In three patients with 
multiple BILAG B organ involvement at baseline, a complete 
resolution in all B-level disease activities by 18 weeks was 
noticed. This clinical improvement was associated with a 
decrease in B-cell levels by 35% at 18 weeks and remained 
low at 6 months post-treatment. There were no safety signals 
and no evidence of immunogenicity or significant changes in 
T-cells, immunoglobulins, or autoantibody levels.23
EMBLEM (NCT00624351)
This is a Phase IIb, 12 week, multicenter, randomized, con-
trolled study that was published in 2013 by Wallace et al. 
The main objective of this trial was to identify appropriate 
safe and effective epratuzumab dosing regimens in patients 
with moderate to severe SLE disease activity.34 The primary 
outcome measure in this study was the BILAG 2004-based 
Combined Lupus Assessment (BICLA). This is a composite Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
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index with five components: 1) BILAG-2004 improvement 
(all A scores at baseline improved to B/C/D, and all B scores 
improved to C or D); 2) no worsening in disease activity 
(no new BILAG-2004 A scores and 1 new B score); 3) no 
worsening of total SLEDAI-2000 (Systemic Lupus Erythe-
matosus Disease Activity Index-2K) score from baseline; 
4) no significant deterioration (10% worsening) in 100 mm 
visual analog physician global assessment; and 5) no treat-
ment failure (defined as non-protocol treatment, ie, new or 
increased immunosuppressives or antimalarials; or increased 
or parenteral corticosteroids; or premature discontinuation 
from study treatment).34 The BICLA response required the 
achievement of all five components.
Two hundred and twenty-seven patients were ran-
domly assigned to one of six treatment groups: placebo or 
epratuzumab 200 mg cumulative dose (cd) (100 mg every 
other week [EOW]), 800 mg cd (400 mg EOW), 2,400 mg 
cd (600 mg weekly), 2,400 mg cd (1,200 mg EOW), or 
3,600 mg cd (1,800 mg EOW). Although the percent-
age of responders was greater in all epratuzumab groups 
compared to placebo, this was not statistically significant. 
In the exploratory analysis, the patients who received 600 
mg weekly (2,400 mg cd) have the higher percentage of 
responders and this was statistically significant with an 
odds ratio of 3.2. In the groups of patients with 2,400 mg 
cd or 3,600 mg cd, the percentage of responders was lower 
than placebo. Starting from week 8, differences in BICLA 
responders were noticed. In this trial, epratuzumab was safe 
and well tolerated with similar rates of adverse events. 
Human anti-human antibody was found in four patients. 
Both ALLEVIATE and EMBLEM Phase IIb showed a 
low response rate in patients receiving a higher dose of 
epratuzumab (3,600 mg cd). Wallace et al explained that 
the high doses of epratuzumab may affect a specific function 
of B-cells or it can induce alternative signaling events not 
seen at lower doses.34 The results from EMBODY 1 are very 
crucial to clarify this phenomenon and are necessary before 
one can draw solid conclusions. 
ALLEVIATE-1 (SL0003) and 
ALLEVIATE-2 (SL0004) – Phase IIb
ALLEVIATE-1 and ALLEVIATE-2 were terminated early 
in September 2006 due to the interruption of drug supply. 
Both studies were randomized, double-blinded, placebo-con-
trolled, and multicenter studies. SL0006 was an open-label 
extension study of patients enrolled in ALLEVIATE.37,38 
Ninety patients were randomized to 36 patients (severe 
BILAG A) in ALLEVIATE I and 54 patients (moderate 
BILAG B) in ALLEVIATE II.38,39 In ALLEVIATE I, 
patients were given either SOC treatment plus repeated 
administrations of epratuzumab 360 mg/m2 (14 patients) or 
720 mg/m2 (eleven patients) or individualized SOC treat-
ment plus placebo (eleven patients). Twenty-eight patients 
in ALLEVIATE II were given SOC treatment plus repeated 
administrations of epratuzumab 360 mg/m2, and 26 patients 
were given SOC treatment plus placebo. In ALLEVI-
ATE, patients had severe lupus with 43% having at least 
one BILAG A. The tapering goals in ALLEVIATE-1 and 
ALLEVIATE-2 were 7.5–10 mg/day and 5–7.5 mg/day 
prednisone (or equivalent) by weeks 20 and 24.
The primary endpoint was BILAG response at week 24 
where all BILAG A scores were reduced to B/C/D and B 
scores to C/D, and no new A and 2 new B scores. The 
primary endpoint response was subsequently redefined for 
12 weeks due to the premature discontinuation of drug supply 
and termination of ALLEVIATE. The exploratory pooled 
analyses of both studies found that responses at week 12 
were 15/34 (44%) and 2/10 (20%) for epratuzumab 360 and 
720 mg/m2, respectively, versus 9/30 (30%) for placebo. 
Total BILAG scores were lower in both epratuzumab groups 
versus placebo (Table 1).
The incidence of adverse events was similar between 
groups with no major side effects. Responders had an 
improvement in the health related quality of life as deter-
mined by SF-36.37,38 In these studies, epratuzumab was well 
tolerated with no safety signals. The frequency of adverse and 
severe adverse events was comparable between epratuzumab 
and placebo arms. 
An open-label extension study 
(SL0006)
Twenty-nine patients from the ALLEVIATE trials continued 
participating in the SL0006 trial. It is important to note that 
there was a delay between completion of the ALLEVIATE 
studies and entry into SL0006 study of a median of 165 days 
(range 1–400 days) which was secondary to the interrup-
tion of the drug supply. Patients received 12 week cycles of 
360 mg/m2 epratuzumab over 100 weeks. Patients in SL0006 
maintained their improvement in disease activity as deter-
mined by SLEDAI/BILAG as well as their improvement in 
SF-36 scores.37,38,40
Although the ALLEVIATE studies were discontinued 
early due to the interruption in drug supply, the analysis from 
the available data showed a potential role for epratuzumab 
in treating SLE. This in turn has led to a Phase III study, 
EMBODY 1, which is currently ongoing and the results are Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
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expected to be released by early 2015. In ALLEVIATE trials 
and the extension study SL0006, epratuzumab treatment 
has led to a clinically important and sustained improvement 
in physicians’ and patients’ global assessment. There was 
also a sustained improvement in health related quality of 
life as determined by SF-36 scores as well as a reduction in 
corticosteroid doses.37
Phase III study (EMBODY 1) 
(NCT01261793; NCT01262365)
 These are Phase III placebo-controlled, randomized, multi-
center studies to assess the efficacy and safety of epratuzumab 
in patients with moderate to severe SLE over four treatment 
cycles, each 12 weeks in duration (48 weeks total). The 
results of these studies are still pending.
Discussion
We have witnessed an advance in the management of SLE 
in the last 5 decades which has led to an improvement in 
patients’ survival.41 A better understanding of lupus patho-
genesis has facilitated the development of new drugs for 
lupus but the conduction and the results of clinical trials 
have been challenging.8 Following the successful story 
of belimumab, there is hope for the future.42 The lupus 
pipeline has several promising drug candidates currently 
in development by different companies.14 The current SOC 
therapy for lupus patients with the use of corticosteroids and 
immunosuppressive drugs is associated with an increased 
risk of infections, hepatic and bone marrow toxicity, and 
other complications. In addition SOC therapy has proven 
ineffective for certain patients, thus, there is an unmet need 
for new drugs in lupus. 
Several biological drugs have been studied for 
the management of active SLE aiming to have safer 
immunosuppression especially with regards to cytotoxicity 
and serious infections. The results of open-label studies of 
rituximab which is a chimeric anti-CD20 monoclonal anti-
body have been promising but their effect was not proven 
in randomized controlled trials.10,11,43,44 Rituximab failed to 
achieve the primary end points in large randomized clinical 
trials (The Exploratory Phase II/III SLE Evaluation of Ritux-
imab [EXPLORER] trial and the Lupus Nephritis Assess-
ment with Rituximab study [LUNAR] trials) on the efficacy 
in treatment of moderate to severe SLE.11 Nevertheless, 
the results from observational studies are encouraging and 
rituximab has been efficient in the treatment of proliferative 
and membranous lupus nephritis.45–47 The discrepancy 
between the results of clinical trials and observational studies 
regarding the efficacy of rituximab suggests that it should 
not be disregarded in the management of lupus.48
Several lessons have been learned from previous tri-
als and it is well accepted that the success and failure of 
a clinical trial depends on several factors in addition to 
the efficacy of the studied drug. The study design and the 
choice of outcomes and endpoints are crucial and affect 
the results of the trials.49,50 The measurement of disease 
activity along with other domains, as recommended by 
the Outcome Measures in Rheumatology, continues to be 
challenging.50 Several lupus disease activity measures have 
been developed and validated and of these, two are com-
monly adopted in clinical trials, SLEDAI-2K – a global 
disease activity index, and the BILAG 2004 – an organ-spe-
cific index, along with the physician global assessment.49,51 
SLEDAI was developed in 1985 and published in 1992, 
and BILAG was published in 1988.52,53 Both indices have 
their advantages and disadvantages. BILAG is a more com-
prehensive index, contains 97 items, and captures disease 
activity over the last 4 weeks. It measures improvement, 
worsening, resolution, persistence, and new occurrences of 
manifestations (not present, improving, same, worse, and 
new). However, BILAG is difficult to use because of its 
complicated glossary and scoring systems.54 SLEDAI-2K 
contains 24 descriptors and captures disease activity over 
4 weeks and records the clinical manifestations as present 
or absent. SLEDAI-2K use is easy to administer and the 
scoring is intuitive which makes it a more viable candidate 
index for use in everyday practice.55,56 Nevertheless, in 
SLEDAI-2K, to demonstrate improvement, a manifestation 
has to resolve completely. Thus, to be able to measure a 
partial improvement in SLEDAI-2K descriptors, it is rec-
ommended to use SLEDAI-2K Responder Index-50.57,58 
SLEDAI-2K Responder Index-50 is able to capture 50% 
improvement in each descriptor and it is currently being 
used in clinical trials for new drugs in lupus.59
Currently, in clinical trials there is a trend to use com-
posite indices. Both composite indices, SLE Responder 
Index (SRI) and BICLA incorporate the SELENA-SLEDAI 
(derivation of SLEDAI), BILAG, and physician global 
assessment. However, in SRI, SELENA-SLEDAI is used 
as the key component and in the BICLA, the key com-
ponent is the BILAG.34,60 SRI and BICLA performances 
were compared to physician-rated improvement (derived 
based on charts’ review) in the Oklahoma cohort study 
retrospectively. This study showed that the BICLA may 
be less sensitive than SRI in capturing improvement. This 
resulted from the fact that “BICLA improvement requires Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
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that all A scores at baseline improved to B/C/D, and all B 
scores improved to C or D, which might be more difficult 
to achieve in patients with multiple organ involvement 
at baseline”, as interpreted by the authors.61 In a post 
hoc analysis, the EMBLEM data were used to compare 
BICLA versus SRI. The SRI response rate was higher 
than the BICLA response rate in the placebo arm and in 
the epratuzumab arm. Authors found that the disagreement 
in BICLA and SRI response rates was attributed to the 
discrepancies between the individual scoring of SLEDAI 
and BILAG items, thus it is very difficult to draw conclu-
sions from this post hoc analysis.62 A similar analysis was 
conducted on the preliminary data of the Biomarkers of 
Lupus Disease (BOLD) study, a study of 100 patients with 
SLE on immunosuppressive therapy. The performance 
of different outcome measures in detecting improvement 
was determined. The analysis at 4 weeks showed that the 
BICLA-like end point was superior to SRI in detecting 
improvement (SRI-4: 48%, SRI-5: 26%, BICLA-similar: 
68%) and at 8 weeks (SRI-4: 67%, SRI-5: 39% and BICLA-
similar: 43%).63 Although the analyses from the above three 
studies did not agree on the performance of BICLA and SRI 
response rates, one can assume that BICLA response rates 
are superior to SRI response rates. This can be attributed to 
the fact that it is easier to capture partial improvement with 
BILAG while it is not possible with SRI where an improve-
ment is based on a complete resolution of the manifestation. 
In conclusion, the potential variability in the application 
of SLEDAI, BILAG, and other indices by physicians in 
multicenter trials, requires the preparedness of investiga-
tors on the use of specific measures, and highlights the role 
of the centralized adjudication committees.8,64
Epratuzumab improved disease activity measures in the 
trials included in this review and was found to have a low 
safety profile. The EMBLEM trial provided us with the most 
effective safe dose of epratuzumab which is a 2,400 mg cd/
cycle (600 mg weekly or 1,200 mg EOW). The ALLEVI-
ATE trial analysis showed clinical meaning improvement 
in BILAG scores as well as improvement in the health 
related quality of life and physician global assessments of 
disease activity with statistically insignificant reduction in 
corticosteroid doses over 12–47 weeks. Nevertheless, some 
of these results were based on pooled analyses of interrupted 
randomized controlled trials and a small number of patients. 
Thus, further results of the ongoing EMBODY 1 study might 
give us better answers on the efficacy of epratuzumab in the 
near future.
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